Sanofi drops plans for messenger RNA vaccine against virus
French drugmaker Sanofi says it is shelving plans for a COVID-19 vaccine based on messenger RNA despite positive results from early stage testing
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.French drugmaker Sanofi said Tuesday it was shelving plans for a COVID-19 vaccine based on messenger RNA despite positive results from early stage testing.
The Paris-based company said it will continue to develop another vaccine candidate that is already undergoing late stage human trials. That vaccine, developed jointly with Britain s GlaxoSmithKline, is based on the characteristic spike protein of the virus that causes COVID-19.
Messenger RNA vaccines use a different technology that uses genetic information from the virus to trigger an immune response. This technology is already being used in the vaccines produced by Pfizer and Moderna.
“From a public health perspective, mRNA COVID vaccines are widely available today, and starting a placebo-controlled study in countries where vaccines are available would be extremely challenging, so it does not make sense for us to further advance our mRNA Covid vaccine into Phase 3,” Sanofi said in response to questions from The Associated Press.
Sanofi recently expanded trials of its recombinant protein vaccine to test its effectiveness as a booster dose to extend immunity for people inoculated with a variety of other vaccines. Results from that study are expected later this year.
While Sanofi has decided not to pursue a COVID-19 vaccine base on messenger RNA technology, the company said early testing showed “promising results.” As a result, Sanofi said it plans to use the technology to develop a new flu vaccine, with clinical studies expected to start next year.
“Today, we have a promising mRNA platform, which we’re taking to the next level in development, including moving to modified mRNA, and against other diseases, including flu,” Jean-Francois Toussaint, global head of research and development at Sanofi’s vaccine unit, said in a statement.